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Steady-state hematopoiesis responds to extracellular stimuli to meet changing
demands and also to pathologically altered intracellular signaling. Granulocyte
production increases following infection or in response to cytokine stimulation,
and activation of the CCAAT ⁄ enhancer-binding protein b (C ⁄ EBPb) transcription
factor is required for such stress-induced granulopoiesis, whereas C ⁄ EBPa plays a
critical role in maintaining steady-state granulopoiesis. Different roles of these C
⁄ EBP transcription factors in different modes of hematopoiesis are evolutionally
conserved from zebrafish to humans. In addition to reactions against infections,
C ⁄ EBPb is responsible for cancer-driven myelopoiesis, which promotes cancer pro-
gression, at least in part, by abrogating the immune response in the cancer
microenvironment. The BCR–ABL fusion protein activates emergency-specific
pathway of granulopoiesis by upregulating C ⁄ EBPb. This in turn causes chronic
phase chronic myeloid leukemia, which is characterized by myeloid expansion.
The C ⁄ EBPb transcription factor also plays a role in other hematological malignan-
cies of both myeloid and lymphoid lineage origin. Thus, elucidation of the
upstream and downstream networks surrounding C ⁄ EBPb will lead to the devel-
opment of novel therapeutic strategies for diseases mediated by non-steady-state
hematopoiesis.
Transcription Factor CCAAT ⁄Enhancer Binding Protein b
C CAAT ⁄Enhancer Binding Protein b (C ⁄EBPb) belongs tothe C ⁄EBP leucine zipper domain-containing family of
transcription factors (Fig. 1).(1,2) This intronless gene product
binds to certain genomic regulatory regions either as a homod-
imer or as a heterodimer with other molecules, including other
members of the C ⁄EBP family. In addition to direct DNA
binding, C ⁄EBPb cooperates with the switch ⁄ sucrose non-
fermentable complex to regulate gene expression through chro-
matin remodeling.(3) It induces or represses the expression of
target genes and, ultimately, regulates the proliferation, differ-
entiation, metabolism, and survival of many different cell
types.(1)
The expression and function of C ⁄EBPb are regulated in a
complex way during transcription, translation, post-translational
modification, and protein–protein interactions.(4–8) Notably,
alternative translation through the use of different initiation
codons generates three different isoforms of C ⁄EBPb: liver-
enriched activating protein* (LAP* or full-length), liver-
enriched activating protein (LAP), and liver-enriched inhibitory
protein (LIP) (Fig. 1).(6) Both LAP* and LAP are transcriptional
activators, whereas LIP (which is the shortest isoform and
lacks transactivation domains but retains DNA binding and
dimerization domains) acts as a repressor or a dominant negative
inhibitor of other C ⁄EBP family transcription factors.(9) The
ratio of these isoforms is regulated by different signaling events
and has a significant impact on the overall function of C
⁄EBPb.(10,11)
Within the hematopoietic system, C ⁄EBPb is expressed at
high levels by monocytes and macrophages, and regulates
genes involved in immune and inflammatory responses.(12–16)
In addition, we found that C ⁄EBPb plays a crucial role in
hematopoiesis, especially under stress conditions.(17–19) Here,
we discuss the role of this transcription factor in non-
steady-state hematopoiesis, including the emergency response
to infection and cancer, and in hematological malignancies.
Modes of Hematopoiesis
Hematopoiesis is a continuous process that supplies an organ-
ism with all blood cells over its lifetime. To avoid either an
excess or lack of any specific type of blood cell, hematopoie-
sis must be tightly regulated according to demand. During
steady-state conditions, the constant production of mature
blood cells is maintained by fine-tuning the proliferation and
differentiation of hematopoietic precursors in both a cell-
intrinsic and a cell-extrinsic manner. By contrast, in emer-
gency situations such as infection or bleeding, large numbers
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of functionally mature cells are required. These increased
demands must be met by an immediate increase in the produc-
tion or release of specific cell types (Fig. 2).(20) These physio-
logical non-steady-state responses are triggered by external
stimuli and are resolved when the activating signals cease. In
addition to responses to infection or bleeding, hematopoietic
stress can be elicited by various kinds of pro-inflammatory
disease, including cancer and autoimmune diseases.(21–24) At
the molecular level, steady-state-specific regulatory mecha-
nisms are thought to be modulated in response to external
stimuli. The shift from steady-state to emergency hematopoie-
sis and vice versa is a continuous process, and the extent of
the shift is dependent on the type, strength, and duration of
the stimuli and ⁄or signals.(20,25) It is difficult to determine
clear boundaries between steady-state and emergency hemato-
poiesis, partly because the shift between these modes may be
an extension of the fine-tuning of steady-state hematopoiesis
mediated by co-operation between steady-state-specific and
emergency-specific signals. Recent studies report the involve-
ment of inflammatory signals in both the development and
ageing of hematopoiesis.(26–28) Therefore, it is necessary to
identify the emergency-specific signals if we are to fully
understand the mechanisms that fine-tune hematopoiesis in
general.
Emergency Granulopoiesis
Neutrophilic granulocytes (granulocytes) are recruited to the
frontline of infection, where they expel their granular contents
to fight microbes.(20,25) In the bone marrow, hematopoietic
stem cells give rise to mature granulocytes through successive
intermediates, such as common myeloid progenitors and gran-
ulocyte–macrophage progenitors.(29) Granulocytes have an
extremely short half-life; therefore, they must be produced
continuously in the bone marrow, stored, and supplied to the
periphery. As is the cases with other hematopoietic lineages,
either an excess or a lack of granulocytes is harmful to the
host; therefore, granulopoiesis must be tightly regulated
according to demand. It is well known that C ⁄EBPa plays
critical roles in granulopoiesis. In Cebpa-deficient mice, tran-
sition from common myeloid progenitors to granulocyte–mac-
rophage progenitors is completely abrogated and no
granulocytes are present under steady-state conditions.(17,30,31)
Overexpression of C ⁄EBPa represses the proliferation of leu-
kemic cells and induces their differentiation into granulo-
cytes.(17,32) Collectively, these findings suggest that C ⁄EBPa
is the master regulator of steady-state granulopoiesis.
While searching for the regulatory mechanisms involved in
emergency granulopoiesis, we found that granulopoiesis can
be induced by cytokines in the absence of C ⁄EBPa. This sug-
gests the existence of a C ⁄EBPa-independent pathway of
granulopoiesis under emergency conditions.(17) Interestingly,
all members of the C ⁄EBP family, except C ⁄EBPb, were
downregulated in response to cytokine stimulation. Cytokine-
or infection-induced enhancement of granulopoiesis is
impaired in Cebpb knockout mice, and the C ⁄EBPa-indepen-
dent pathway of granulopoiesis is significantly attenuated by
inhibiting C ⁄EBPb.(17) By contrast, C ⁄EBPb is not necessary
for steady-state granulopoiesis. These results clearly suggest
that C ⁄EBPb is required for stress-induced granulopoiesis;
indeed, this requirement has been verified in other mouse
models and in a zebrafish model.(33–35) Both C ⁄EBPb and
C ⁄EBPa share many common target molecules, including
genes associated with granulocytic differentiation.(36) By con-
trast, they show a differing ability to regulate the cell cycle.
C ⁄EBPa strongly inhibits the cell cycle through direct or
indirect interactions with cell cycle regulators,(37–39) whereas
C ⁄EBPb has a less inhibitory effect.(17,40) These differences
might be the reason for the selective requirement of C ⁄EBPa
and C ⁄EBPb for steady-state and emergency granulopoiesis,
respectively. As the transition from steady-state to emergency
granulopoiesis (or vice versa) is a continuous process,
C ⁄EBPa or C ⁄EBPb might collaborate with each other to
ensure an adequate supply of granulocytes by fine-tuning the
proliferation and differentiation of granulocyte precursors
(Fig. 3). Furthermore, we also found that CEBPb is required
by early granulocyte precursors under emergency conditions;







Fig. 2. Modes of hematopoiesis. The hematopoietic system in the
bone marrow supplies mature blood cells on demand. Under both
steady-state and emergency conditions, overlapping and distinct sig-
nals ensure the adequate production and release of mature cells. Red
arrows indicate extracellular stimuli, including infection and cancer.
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Fig. 1. Schematic illustration of the C ⁄ EBPb transcription factor and
its isoforms. A, transactivating domain; BR-LZ, basic region–leucine
zipper domain; LAP*, liver-enriched activating protein*; LAP, liver-
enriched activating protein; LIP, liver-enriched inhibitory protein; R,
repression domain.
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Role of C ⁄EBPs in the Pathophysiology of Severe
Congenital Neutropenia
Severe congenital neutropenia (SCN) is an inherited condition
characterized by severe neutropenia in the peripheral blood
(<500 ⁄lL) and by arrest of myeloid precursor maturation at
the promyelocyte ⁄myelocyte stage in the bone marrow, result-
ing in increased vulnerability to bacterial and fungal infec-
tions.(41,42) The majority of patients with SCN respond to
treatment with recombinant granulocyte-colony stimulating
factor, which increases the neutrophil count and reduces both
the frequency and severity of infections. Patients with SCN
harbor mutations in diverse genes. These heterogeneous
genetic alterations reflect the complex mechanisms governing
the homeostasis of neutrophils.(42) Establishing induced plurip-
otent stem cells from SCN cells in combination with an in vitro
differentiation system will further our understanding of both
the pathogenesis of this disease and the physiological regula-
tion of granulopoiesis.(43,44) The majority of SCN patients har-
bor mutations in ELANE and HAX1 (approximately 60% and
10%, respectively).(45) Recently, the lymphoid enhancer-
binding factor 1 (LEF-1) transcription factor was identified as
a common factor responsible for defective granulopoiesis in
SCN patients with mutations in ELANE (ELA2) or HAX1.(46)
LEF-1 regulates C ⁄EBPa during granulopoiesis. Both the
expression and function of LEF-1 and C ⁄EBPa are severely
reduced in myeloid precursors in SCN patients with ELANE
or HAX1 mutations, and the reduction in C ⁄EBPa (the master
regulator of steady-state granulopoiesis) might be a critical
mechanism underlying neutropenia in SCN.(46,47) Maturation
arrest can be overcome by treatment with granulocyte-colony
stimulating factor, presumably because it activates the
C ⁄EBPb-mediated pathway of granulopoiesis, which is thought
to be intact in SCN patients.(48) The new insights into the path-
ophysiology of SCN suggest that the different roles of
C ⁄EBPa and C ⁄EBPb during granulopoiesis may also be true
in humans.
Cancer-associated Myelopoiesis
Cancer progression, including tumor growth, invasion, and
metastasis, cannot be achieved by tumor cells alone; it requires
the appropriate microenvironment.(49,50) Accumulating
evidence suggests that myeloid cells are major components of
the cancer microenvironment.(21–23) Indeed, there is a strong
association between increased numbers of macrophages or neu-
trophils in cancer tissues and poor patient survival.(51,52) Thus,
these myeloid cells can be good candidate therapeutic targets.
Tumor cells, or other stromal cells, in the microenvironment
produce a variety of growth factors and chemokines, which
then recruit myeloid cells from the bone marrow or reservoir
tissues.(21–23) Therefore, the mode of hematopoiesis is altered
in the presence of cancer, and hematopoietic systems release a
variety of myeloid cells into the cancer microenvironment.
Such cells include monocytes, macrophages (tumor-associated
macrophages), dendritic cells, neutrophils (tumor-associated
neutrophils), and eosinophils. Recent studies by ourselves and
others identified fibrocytes as important constituents of the
cancer microenvironment.(53–55) In such microenvironments,
myeloid cells support cancer progression by secreting growth
factors and promoting angiogenesis and ⁄or tissue remodeling.
In addition, it is widely accepted that a special subset of mye-
loid cells, called myeloid-derived suppressor cells (MDSCs),
are induced by tumor-induced factors and are responsible for
immune dysfunction.(22,56) MDSCs in mice are classified as
either monocytic or granulocytic based on their surface expres-
sion of Ly6C and Ly6G, respectively. Upregulated in the bone
marrow of tumor-bearing hosts, C ⁄EBPb regulates the expres-
sion of enzymes such as arginase and inducible nitric oxide
synthase, both of which are required for the lymphocyte-inhibi-
tory activities of MDSCs (Fig. 4a).(57) Accordingly, in tumor-
bearing mice, both the emergence and the immunosuppressive
function of MDSCs are severely abrogated in the absence of
C ⁄EBPb, resulting in attenuated tumor spread.(57) A similar
relationship between C ⁄EBPb and cancer-driven myelopoiesis
is observed in humans.(58) These findings suggest that C ⁄EBPb
plays a critically important role in cancer-induced inflamma-
tion; thus, C ⁄EBPb may be a therapeutic target for regulating
the cancer microenvironment. Further studies should examine
the roles of C ⁄EBPb in generating or regulating the function
of MDSCs in other diseases.
Role of CEBPb in Chronic Myeloid Leukemia
Chronic phase chronic myeloid leukemia (CP-CML) is charac-
terized by a massive expansion of myeloid cells.(59) In sharp
contrast to acute myeloid leukemia (AML) with leukemic hia-
tus, both myeloid progenitors and mature granulocytes accu-
mulate in the bone marrow, peripheral blood, and spleen in
CP-CML. The myeloid expansion in CP-CML is attributed to
the BCR–ABL fusion protein, which arises from a transloca-
tion between chromosomes 9 and 22.(59) The leukocytosis
observed in patients with infections, severe burns, or cancer is
sometimes referred to as a “leukemoid” reaction because of
the marked increase in the number of myeloid cells with a
“left shift” in the shape of the nucleus. The resemblance
between leukemoid reactions and CP-CML prompted us to
examine whether BCR–ABL might use the emergency-specific
pathway of granulopoiesis. Therefore, we investigated the role
of C ⁄EBPb in CP-CML (Fig. 4b). BCR–ABL upregulates
C ⁄EBPb, at least in part, by activating signal transducer and
activator of transcription 5.(19) Myeloid differentiation and pro-
liferation (induced by BCR–ABL) are significantly impaired in
Cebpb-deficient bone marrow cells both in vitro and in vivo.(19)
Interestingly, higher numbers of Cebpb-deficient leukemic stem
cells were maintained after serial transplantation than wild-type






Fig. 3. Role of C ⁄ EBP transcription factors in steady-state and emer-
gency granulopoiesis. Activation of the C ⁄ EBPb transcription factor is
required to generate increased numbers of granulocytes under emer-
gency conditions, such as severe infection or cytokine exposure,
whereas C ⁄ EBPa plays a critical role under steady-state conditions.
C ⁄ EBPb and C ⁄ EBPa share many common target molecules, including
genes associated with granulocytic differentiation. By contrast, they
show a differing ability to regulate the cell cycle. C ⁄ EBPa strongly
inhibits the cell cycle, whereas C ⁄ EBPb has a less inhibitory effect. Red
arrows indicate extracellular stimuli that activate C ⁄ EBPb.
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gest that C ⁄EBPb is involved in BCR–ABL-mediated myeloid
expansion and leukemic stem cell exhaustion in CP-CML.
Consistent with our observations, C ⁄EBPb is markedly upregu-
lated in a pluripotent hematopoietic cell line transduced with
BCR–ABL.(60) By contrast, downregulation of C ⁄EBPb is
associated with progression of CML toward a blast crisis.(61)
Changes in the BCR–ABL-mediated regulation of C ⁄EBPb
during the progression of CML may be a consequence of
genetic or epigenetic changes. Isoforms of C ⁄EBPb involved
in the pathogenesis of CML remain to be identified. Further
identification of the molecular mechanisms underlying the reg-
ulation of C ⁄EBPb and C ⁄EBPb-mediated leukemic stem cell
exhaustion might lead to novel therapeutic strategies for eradi-
cating CML stem cells.
Role of CEBPb in other Hematological Malignancies
Hematological malignancies are the consequence of dysregu-
lated differentiation and ⁄ or proliferation; therefore, they can be
regarded as a form of pathologically induced non-steady-state
hematopoiesis. Because C ⁄EBPa promotes neutrophilic differ-
entiation and inhibits the cell cycle, many cases of AML are
associated with recurrent mutations in, or dysregulation of,
C ⁄EBPa.(62–64) By contrast, no recurrent mutations in C ⁄EBPb
have been identified in AML,(65) possibly reflecting the fact
that this transcription factor is required for emergency-specific
responses. However, C ⁄EBPb plays a role in the pathogenesis
of many hematological malignancies. In AML, LIP (the short-
est isoform of C ⁄EBPb) collaborates with a proto-oncogene,
Evi1, to induce leukemia in a mouse bone marrow transplanta-
tion model.(66) The same isoform is induced by signaling
downstream of internal tandem duplication of fms-like tyrosine
kinase 3, thereby supporting the proliferation of blasts.(67)
These findings suggest that regulating the amount or the ratio
of C ⁄EBPb isoforms might be a common pathway that is abro-
gated during the development of AML.
Acute promyelocytic leukemia (APL) is a subtype of AML
characterized by a promyelocytic leukemia-retinoic acid recep-
tor a(PML-RARa)-mediated differentiation block at the promy-
elocyte stage, which occurs (at least in part) through an
impairment in C ⁄EBPa function.(68) This block is reversed by
all-trans retinoic acid (ATRA), which is used as frontline ther-
apy for APL.(69) After the start of ATRA treatment, mature
neutrophil-like cells originate from leukemic promyelocytes
and their numbers increase in the bone marrow and peripheral
blood of responder APL cases. During this process of differen-
tiation-inducing therapy, C ⁄EBPb is upregulated in the pres-
ence of PML-RARa and increases the number of neutrophils
derived from APL cells by promoting their proliferation and
differentiation (Fig. 4c).(70) In other words, C/EBPb is an
ATRA-dependent PML-RARa target gene in APL cells.
It is clear that C ⁄EBPb regulates not only myeloid hemato-
poiesis, but also bone marrow B lymphopoiesis, in both a cell-
intrinsic and cell-extrinsic manner.(71,72) One study examined
the contribution of C ⁄EBPb to the development of lymphoid
neoplasias in cases with acute B-cell precursor leukemia and
identified recurrent translocations in C ⁄EBPb, which resulted
in the upregulation of C ⁄EBPb.(73)
Anaplastic large cell lymphoma (ALCL) is a subset of non-
Hodgkin’s lymphoma characterized by unique cell morphology
and expression of CD30.(74) In ALCL cells, the anaplastic lym-
phoma kinase (ALK) gene is frequently fused to the nucleophos-
min (NPM) gene, and the resulting ALK activity is the central
driver for the survival of ALCL cells. Recently, C ⁄EBPb was
identified as a downstream target of ALK-mediated signal-
ing.(74) C ⁄EBPb is upregulated in the presence of activated
ALK through signal transducer and activator of transcription
3(74,75) or by post-transcriptional regulation,(76) whereupon it
contributes to the transformation and survival of ALCL cells.(77)
The pathogenesis of multiple myeloma remains unclear and,
at present, this plasma cell disorder is incurable. A recent
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Fig. 4. Involvement of C ⁄ EBPb in non-infectious modes of hemato-
poiesis. (a) C ⁄ EBPb is upregulated in the bone marrow of tumor-bear-
ing hosts. C ⁄ EBPb regulates the differentiation of myeloid-derived
myeloid suppressor cells (MDSCs) and the expression of enzymes such
as arginase and inducible nitric oxide synthase (iNOS), both of which
are required for the lymphocyte-inhibitory activities of MDSCs. (b) In
chronic phase chronic myeloid leukemia (CML), C ⁄ EBPb is activated by
signal transducer and activator of transcription 5 (STAT5), which is
located downstream of BCR–ABL. C ⁄ EBPb is involved in BCR–ABL-med-
iated myeloid expansion and leukemic stem cell exhaustion in chronic
phase CML. (c) Acute promyelocytic leukemia (APL) is characterized by
a promyelocytic leukemia-retinoic acid receptor a(PML-RARa)-medi-
ated differentiation block at the promyelocyte stage. During the pro-
cesses of differentiation-inducing therapy using all trans retinoic acid
(ATRA), C ⁄ EBPb is upregulated in the presence of PML-RARa and
increases the number of neutrophils derived from APL cells by pro-









Fig. 5. Role of C ⁄ EBPb and non-steady-state hematopoiesis. Different
types of cell-extrinsic stress, including infections and cancer, activate
C ⁄ EBPb to increase the supply of functionally mature myeloid cells or
myeloid-derived suppressor cells. Dysregulation of C ⁄ EBPb is observed
in some hematological malignancies, resulting in maintenance or pro-
gression of disease.
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and is involved in regulating several transcription factors,
including IRF4, XBP1, and BLIMP1, all of which are critical
for the proliferation and survival of myeloma cells.(78) Inhibit-
ing C ⁄EBPb translation in myeloma cells using immunomodu-
latory derivatives of thalidomide has been proposed as a novel
therapeutic strategy for multiple myeloma.(79)
Conclusions
The expression and ⁄or function of C ⁄EBPb are upregulated
in the hematopoietic system in response to various kinds of
cell-extrinsic stress, including infections and cancer. This
upregulation increases the supply of myeloid cells. Dysregu-
lation of C ⁄EBPb is observed in several hematological
malignancies, resulting in the maintenance or progression of
disease. Although the roles of C ⁄EBPb in hematopoiesis
have not been fully elucidated, it appears to play a key role
in non-steady-state hematopoiesis, including hematological
malignancies, and hematopoiesis in host with cancers in
addition to hematopoietic responses against infections
(Fig. 5). Even though direct targeting of this transcription
factor might be technically difficult, identifying the upstream
and downstream networks involving C ⁄EBPb will lead to a
better understanding of the pathogenesis and pathophysiology
of diseases mediated by non-steady-state hematopoiesis.
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